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A REAL-TIME QUANTITATIVE ASSAY FOR HEPATITIS B DNA VIRUS (HBV) DEVELOPED TO DETECT 
ALL HBV GENOTYPES
Roberta SITNIK(1), Ângela PAES(2), Cristovão Pitangueira MANGUEIRA(1,3) & João Renato Rebello PINHO(1,4)
SUMMARY
Hepatitis B virus (HBV) is a major cause of chronic liver disease worldwide. Besides genotype, quantitative analysis of HBV 
infection is extensively used for monitoring disease progression and treatment. Affordable viral load monitoring is desirable in 
resource-limited settings and it has been already shown to be useful in developing countries for other viruses such as Hepatitis C 
virus (HCV) and HIV. In this paper, we describe the validation of a real-time PCR assay for HBV DNA quantification with TaqMan 
chemistry and MGB probes. Primers and probes were designed using an alignment of sequences from all HBV genotypes in order 
to equally amplify all of them. The assay is internally controlled and was standardized with an international HBV panel. Its efficacy 
was evaluated comparing the results with two other methods: Versant HBV DNA Assay 3.0 (bDNA, Siemens, NY, USA) and another 
real-time PCR from a reference laboratory. Intra-assay and inter-assay reproducibilities were determined and the mean of CV values 
obtained were 0.12 and 0.09, respectively. The assay was validated with a broad dynamic range and is efficient for amplifying all HBV 
genotypes, providing a good option to quantify HBV DNA as a routine procedure, with a cheap and reliable protocol. 
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INTRODUCTION
Hepatitis B virus (HBV) is a major cause of chronic liver disease 
worldwide. This virus is a small DNA virus with a partially double-
stranded 3.2 kb genome and has been classified into eight genotypes 
(A-H) based on sequence divergence over the entire genome16-18. These 
genotypes have a distinct and well established geographic distribution15 
and impact disease prognosis and progression. In Brazil, genotypes A, 
D and F are the most prevalent, but genotypes B, C, E and G have also 
been reported3,5,23,25,26. 
Besides genotype, the quantitative analysis of HBV DNA is 
extensively used for monitoring disease progression and treatment of 
HBV infection. Commercial assays are available for quantification of 
HBV DNA, such as the Versant HBV DNA Assay 3.0 (bDNA - Siemens 
Medical Solutions Diagnostics, Tarrytown, NY, USA) with a dynamic 
range from 2 X 103 to 1 X 108 copies/mL30 and the Amplicor HBV Monitor 
Test (Roche, Alameda, CA, USA), with a dynamic range from 2 X 102 to 
2 X 105 copies/mL11. Recently, several real-time PCR-based HBV DNA 
quantification assays have also been developed with the advantages of 
increased sensitivity, broader linearity and less carryover contamination 
risks1,13,20. Real time PCR based kits for HBV detection have also been 
launched by diagnostic companies and are currently replacing former 
HBV DNA amplification kits, such as the COBAS TaqMan 48 real-time 
PCR system (Roche Molecular Systems, Branchburg, NJ), and the Abbott 
Real Time HBV Quantification kit (Abbott Laboratories, USA)2,9,28.
Affordable viral load monitoring is desirable in resource-limited 
settings and it has already been shown to be very useful in developing 
countries for the Hepatitis C virus (HCV) and HIV7,8,22,24,27. In this paper, 
we describe the validation of a real-time PCR quantitative assay (qPCR) 
for HBV DNA based on TaqMan technology and MGB probe, which 
have a large dynamic range and can amplify all known HBV genotypes.
MATERIALS AND METHODS
Patients and clinical samples: For initial standardization, two 
international HBV reference plasmas developed by BBI Diagnostics 
(West Bridgewater, MA, USA) were used: PHD801 (concentration of 
4.3 X 106 IU/mL diluted from 1 to 500,000X, genotype A) and QHD701 
(concentration of 1.19 X 106 IU/mL diluted from one to 15,000X, 
genotype A). 
Clinical samples stored at -80 oC were obtained from 95 patients from 
other studies. The study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki as reflected in a priori approval by the Ethical 
Committee from Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. 
Written informed consent was obtained from each patient in the study.
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HBV genotypes had already been determined as previously 
described25 and samples representing genotypes A, B, C, D, E and F 
were chosen to verify the detection of them with the new assay. Genotype 
distribution was: A - 36.1%; B - 2.8%; C - 25.0%; D - 25.0%; E - 2.8% 
and F - 8.3%. For specificity analysis, samples obtained from 40 healthy 
blood donors provided by the Hospital Albert Einstein Blood Bank were 
assayed. These samples were seronegative for HBsAg, anti-HBc, anti-
HCV, anti-HIV, Treponema pallidum and Trypanosoma cruzi.
Primers and probe design: The PCR primers and probe were 
designed in order to equally amplify all known HBV genotypes. In this 
way, an alignment with sequences of all HBV genotypes described in a 
previous study with Brazilian patients25 and sequences from GenBank 
was carried out and a well conserved region among all genotypes in 
the S gene was selected. After this, PCR primers and TaqMan MGB 
probe sequences were checked concerning base composition, melting 
temperatures, GC content, internal folding using Primer Express software 
(Applied Biosystems, Foster City, CA, USA). 
DNA extraction: For the isolation of HBV DNA from plasma, the 
QIAamp DNA mini kit (QIAGEN, Hilden, Germany) was used, following 
manufacturer’s instructions. DNA was extracted from 200 μL plasma 
with 1 μL of the internal control (1X IPC DNA; Applied Biosystems, 
Foster City, CA, USA) and eluted in 50 μL buffer.
HBV quantification by versant HBV DNA assay: The Versant 
HBV DNA Assay version 3.0 (bDNA - Siemens Medical Solutions 
Diagnostics, Tarrytown, NY, USA) was performed in accordance with 
the manufacturer’s protocol. 
Real-Time PCR assay (qPCR): Amplification was performed in a 
50 μL reaction mixture containing: 1X TaqMan Universal PCR Master 
Mix, 20 μM of each primer and probe, and 5 μL of extracted DNA. All 
samples were performed in duplicate. As an internal control, we used the 
TaqMan Exogenous Internal Positive Control Reagents kit with 1X IPC 
Mix (primers and TaqMan probe labeled with VIC) and 1X IPC DNA. All 
reagents were obtained from Applied Biosystems (Foster City, CA, USA). 
Absolute quantification of HBV DNA was performed with ABI 
PRISM 7500 Real Time (Applied Biosystems, Foster City, CA, USA). 
Amplification starts with an incubation at 50 oC for two min for uracil 
N’-glycosylase inactivate possible contaminating amplicons, followed by 
10 min at 95 oC that activates AmpliTaq Gold Polymerase and inactivates 
uracil N’-glycosylase. PCR cycling program consisted of 45 two-step 
cycles of 15 s at 95 oC and 60 s at 60 oC (universal conditions). 
For validation of the method, qPCR assay for HBV DNA was first 
validated using two international HBV reference plasmas developed by 
BBI Diagnostics (West Bridgewater, MA, USA): PHD801 (concentration 
of 4.3 X 106 IU/mL diluted from one to 500,000X, genotype A) 
and QHD701 (concentration of 1.19 X 106 IU/mL diluted from one 
to 15,000X, genotype A). Afterwards, linearity of the test was also 
performed with samples of genotype D and F.
qPCR results were also compared with one other available assay: 
Versant HBV DNA Assay version 3.0 (bDNA - Siemens Medical 
Solutions Diagnostics, Tarrytown, NY, USA) (n = 58) and samples 
were also sent to a reference laboratory (Quest diagnostics, San Juan 
Capistrano, CA, USA) (n = 56). The method used in this test is real-time 
PCR of the precore/core region of the HBV genome. It has a linear range 
from 102 to 5 X 109 IU/mL and was developed by Quest Diagnostics 
Nichols Institute (San Juan Capistrano, CA, USA) 
Inter- and intra-assay reproducibilities were examined using two 
clinical samples (A - 7.25 log IU/mL, Genotype C; and B - 7.40 log IU/
mL, Genotype A) at different dilutions. Detection limit was established 
by testing samples of the most common genotypes found in Brazil (A, D 
and F) in different concentrations (20, 50, 100 and 150 IU/mL).
Preparation of standard: One sample with a very high viral load 
(6.27 logIU/mL, genotype C) was selected and diluted in normal plasma 
to be used as a quantification standard. This diluted sample was frozen 
at -80 oC in 200 μL aliquots in order to preserve its viral load. It was 
then tested in triplicate using the international panel as a quantification 
control, and the obtained result was compared to the external reference 
laboratory and bDNA. In every routine, this sample was extracted, diluted 
from 10-1 to 10-6 and used as a quantification control.
Statistical analysis: Validation of qPCR was analyzed by scatter, 
Bland-Altman plots4 and linear regression. Intercept was not considered 
in order to evaluate the slope of fitted line. For reproducibility analyses, 
viral loads were summarized by means of standard deviations (SD) 
and coefficient of variation (CV). Scatter and Bland-Altman plots were 
also used to compare qPCR with other methods. Pearson’s correlation 
coefficients were computed. All analyzes were performed using Excel 
and SAS statistical package, version 9.01.
RESULTS
Primers and probe design: After alignment of sequences previously 
described in the GenBank, conserved regions in the S gene region of 
HBV DNA were selected and analyzed by Primer Express software 
(Applied Biosystems, Foster City, CA, USA), considering the best fitted 
combination of primers and probe. 
The selected sequences are:
Primer forward: 5’ CCT GGY TAT CGY TGG ATG TGT 3’
Primer Reverse: 5’ GGA CAV ACG KGC AAC ATA CCT T 3’
Probe: 5’ 6FAM CTA TGC CTC ATC TTC TT MGB NFQ 3’
PCR product is 116 bp and position of primers and probe on reference 
HBV strains of different genotypes is shown in Fig. 1.
Validation with international panels: The log10 values of all 
international HBV reference plasmas samples were plotted against 
expected results and regression analysis (without intercept) showed 
that the slope approached 1.0 with R2 = 0.996 (Fig. 2A). Bland-Altman 
plot shows most of points are within 95% limits of agreement (Fig. 2B). 
Results of  genotypes A, D and F samples diluted at different viral 
load levels showed that the test had a linear range from 50 to 1 X 108 
IU/mL, or 1.70 to 8.0 log IU/mL. Samples below 50 IU/mL could be 
detected, but not every time tested, and detection limit was established 
as 50 IU/mL, with 92% confidence interval. Samples with viral loads 
higher than 108 IU/mL had results below the expected, and must be 
diluted (data not shown). 
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the samples for 12 consecutive days and intra-assay variability was 
evaluated by running 10 determinations for each sample. Results of viral 
load means, standard deviation (SD) and coefficient of variation (CV) 
are shown in Table 1. One sample (B) was diluted to 1.40 log IU/mL 
and could not be detected in all runs, but it was below the established 
detection limit of 1.70 log IU/mL. 
Specificity: None of the 40 samples from healthy blood donors had 
detectable results for HBV DNA, tested in duplicate. Negative controls 
(NC) were also processed in every reaction in a proportion of one NC 
for every five-tested sample. Negative results were obtained every time 
for those samples.
Fig. 1 - Alignment of different HBV genotypes and subgenotype strains from GenBank showing the localization of primers and probe selected for the HBV qPCR.
Fig. 2 - Scatter plot (A) and Bland-Altman (B) of the comparisons between qPCR and 
International HBV reference plasmas. In Fig. A, the dotted line refers to diagonal (y = x).
Table 1











High (pure) - A 12 7.25 7.13 (0.07) 0.01
High (pure) - B 12 7.40 7.29 (0.07) 0.01
Low (10-5) - A 12 2.25 2.23 (0.31) 0.14
Low (10-6) - B 10 1.40 1.33 (0.35) 0.26
Intra-assay
High (pure) - A 10 7.25 7.00 (0.04) 0.01
High (pure) - B 10 7.40 6.79 (0.05) 0.01
Intermediate (10-3) - A 10 4.25 4.34 (0.08) 0.02
Intermediate (10-3) - B 10 4.40 4.14 (0.04) 0.01
Low (10-5) - A 10 2.25 2.73 (0.16) 0.06
Low (10-6) - B 8 1.40 1.63 (0.15) 0.09
a
 mean CV interassay: 0.12; b mean CV intra-assay: 0.03
Influence of Internal Control primers and probe was tested by parallel 
reactions performed with and without them. HBV viral load was the same 
in both reactions showing no competition. Besides, internal control was 
detected in all samples with viral load below 106 IU/mL.
Reproducibility: Interassay variability was determined by running 
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Correlation between real time and other HBV DNA assays: The 
HBV DNA real-time PCR detection assay was compared with Versant 
HBV DNA Assay version 3.0 (bDNA - Siemens Medical Solutions 
Diagnostics, Tarrytown, NY, USA) (n = 58) and samples were also 
sent to a reference laboratory (Quest diagnostics, San Juan Capistrano, 
CA, USA) (n = 56). The log of viral load values (IU/mL) obtained was 
plotted against values obtained from reference laboratory (Fig. 3A) 
and bDNA (Fig. 3C). It is noteworthy that some samples were detected 
only by the qPCR here described. Linear correlation coefficient based 
on only detectable (or undetectable) viral loads by both methods were 
high (r = 0.984 for reference laboratory and r = 0.966 for bDNA). In 
Bland-Altman plots (Fig. 3B and 3D), only one sample with high viral 
load in Figure 3D had absolute difference between qPCR and bDNA, 
higher than expected. This sample was genotype A and had a viral load 
of 9.82 log IU/mL, above our linear range, and should be diluted. Other 
samples that exceed 95% limits of agreement correspond to low viral 
load samples, which were detected only by qPCR method. Samples with 
different viral load levels were tested for each genotype.
DISCUSSION
HBV viral load measuring is a very important tool for monitoring 
HBV infected patients. There is an increasing trend for the use of 
combination of nucleotide analogs, which lead to a fast dynamic of viral 
load. It is expected that monitoring the HBV viral load together with the 
detection of resistance related mutations in the HBV genome will be able 
to provide clinicians with important guidelines for the HBV treatment. 
The most direct and reliable measurement of viral replication is HBV 
DNA quantification that can replace other indirect methods to assess the 
efficacy of antiviral therapy used to treat HBV infected patients, such as 
serologic markers or measurement of liver enzyme function. Histology is 
adequate to evaluate the efficacy of a treatment, however, lacks the ability 
to discriminate rapidly any difference at multiple time points in clinical 
trials, comparing active drugs or combination therapy. Monitoring the 
HBV viral load can predict the evolution to cirrhosis and hepatocellular 
carcinoma6, as well as a rapid and sustained response to treatment, as a 
predictive factor for a favorable treatment outcome. It can also provide an 
early detection of treatment failure that may be related to poor adherence 
to therapy or selection of a resistant virus. The likelihood of resistance to 
nucleos(t)ide analogues is very low when HBV-DNA level is undetectable 
during therapy and increases proportionally to the HBV-DNA level21.
An assay with a lower limit of detection of 103 IU/mL may be 
sufficient to monitor and manage the patient but, in some instances a more 
sensitive assay with a lower limit of detection of the order of 101 IU/mL 
may be required to ensure detection of the emergence of resistance as 
early as possible. Our results have shown that we could detect samples 
with viral load below 50 IU/mL. An example can be seen in Table 1, 
where Sample B - Low (10-6) could not be detected in 2/12 times in the 
interassay test and in 2/10 times in the intra-assay test. A dynamic range 
of quantification of at least 5 log10 is also recommended and samples 
with an HBV-DNA level above the upper limit of detection of the assay 
should be diluted and retested to provide an end point. For all of these 
reasons, real-time PCR quantification assays are strongly recommended 
Fig. 3 - Comparisons between qPCR and reference laboratory (A and B) and bDNA (C and D). In Fig. A and C (Scatter plots), the dotted lines refer to minimum detection limit for each method 
while Figures B and D show Bland-Altman comparisons between the two methods.
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over other technologies, especially in clinical trials, because they are 
very sensitive and have a broad dynamic range of quantification1,13,14,19,21.
Early predictors of the treatment efficacy at week 24 include (1) 
complete virologic response, defined as a decrease in HBV DNA to < 60 
IU/mL; (2) partial virologic response (HBV DNA 60 to < 2000 IU/mL); or 
(3) inadequate virologic response (HBV DNA ≥ 2000 IU/mL). Treatment 
recommendations vary depending on which of these categories a patient 
falls into. For patients who have an ideal response to therapy (complete 
virologic response), the panel recommends maintaining treatment with 
no change and broadening the interval for monitoring. Treatment should 
be continued without change for patients who have an adequate response 
to therapy (partial virologic response) and monitoring should be more 
frequent. For patients who have a suboptimal response or no response 
to therapy, the panel recommends switching to or adding alternative 
therapy with no overlapping resistance mutations and continuing to 
monitor frequently10.
Although we have only tested this assay with samples harboring 
genotypes A to F during the validation process, the primer sequences 
chosen were also covered for genotypes G and H, which are more similar 
to genotypes A and F, respectively. Afterwards, the protocol was established 
in the routine laboratory and more than 1,500 clinical samples were already 
analyzed, including genotypes A to G. Proficiency test samples (Hepatitis 
Viral Load Survey from the College of American Pathologists - CAP and 
Molecular Biology Panel from ControlLab, SBPC/ML) were also analyzed 
with satisfactory results in the last two years. 
In Brazil, only a few commercial HBV quantification assays are 
available; and several in house assays described before have some 
limitations, such as lack of internal control, a small linear range or 
allowing analysis of only a few HBV genotypes1,13,14,20.
When conducting this work, we were able to compare our test with 
the only commercial available kit (bDNA) and it was possible to verify 
its low sensibility, linked to the principle of the method. Nowadays, other 
commercial kits have been released, such as the Cobas Taqman HBV 
test (Roche) and Abbott Real Time HBV assay, but these kits are more 
expensive and not commercially available in many countries. Otherwise, 
this is an open protocol that allows HBV quantitation in resource-limited 
settings, providing a cheap and effective alternative to existing HBV 
assays. It has already been shown in other studies that in house testing for 
HCV and HIV detection and quantitation7,8,22,24,27 can be used routinely, 
provided high level quality control rules are followed.
An underestimation of the HBV viral load of genotype F samples 
with the Cobas Monitor PCR system has been reported12. As genotype F 
is mainly present in Central and South America and is relatively common 
among our patients in this case25, quantification of this genotype is very 
important in Brazil. In the COBAS Taqman HBV Test this problem seems 
to be solved and it equally amplifies genotypes A-G. The linear range 
of this test is from 29 to 1.1 X 108 IU/mL and the probes are directed to 
the pre-core/core region of HBV2,29.
The Abbott Real Time HBV kit is also a real time PCR based kit, all 
HBV genotypes (A-H) can be adequately detected, results in IU/mL or 
copies/mL, dynamic range from 10 to 109 IU/mL. The probes are in the 
S region of HBV genome28.
The standardization of quantification units is another important 
issue when measuring HBV viral load. Serum HBV-DNA levels are 
reported in many different units depending on the method used and the 
manufacturer of the assay (eg, copies/mL, genome equivalents - Eq/mL, 
mega-equivalents - MEq/mL, or international units -IU/mL). The World 
Health Organization has defined an international standard for HBV DNA 
nucleic acid amplification techniques that has been used to calibrate the 
IU/mL. Several HBV-DNA quantification assays that are available have 
been normalized to the World Health Organization international standard, 
such as the Abbott Real Time HBV kit and the COBAS Taqman HBV Test. 
Serum HBV-DNA levels should now be expressed universally in IU/mL in 
all available assays to ensure comparability between the assays, between 
different trials in which different assays have been used, and to allow the 
creation of guidelines that can be applied to whatever assay was used21.
In the test described here, many limitations of other methods were 
considered. Since conserved regions were chosen from the alignments of 
all HBV genotypes (A-H) during primer and probe design; and genotypes 
A-F infected patients were tested, this assay showed efficacy to amplify all 
genotypes circulating in Brazil. The use of an internal control, extracted 
together with the sample, is able to detect the presence of inhibitors in the 
sample. The standard curve was normalized to IU/mL, and this qPCR is 
sensitive, accurate and reproducible allowing the quantification of HBV 
DNA, particularly useful for following chronic HBV carriers. The assay 
was implemented in the diagnostic routine from a clinical laboratory and 
has proved to be highly cost efficient. 
RESUMO
Ensaio quantitativo em tempo real para o DNA do vírus da hepatite 
B (HBV) desenvolvido para detectar todos os genótipos do HBV
O vírus da Hepatite B (HBV) é uma das principais causas de doença 
crônica do fígado no mundo. Além do genótipo, a análise quantitativa 
do HBV é amplamente utilizada para monitorar a progressão da doença 
e o tratamento. Em locais com recursos escassos, métodos baratos 
para o monitoramento da carga viral são desejáveis e, em países em 
desenvolvimento, sua utilidade já foi demonstrada para outros vírus, 
como o da Hepatite C e HIV. Neste trabalho, descrevemos a validação de 
um teste de PCR em Tempo Real para a quantificação do DNA do HBV 
utilizando sondas Taqman/MGB. Os oligos e sondas foram escolhidos 
usando um alinhamento contendo seqüências de todos os genótipos do 
HBV para garantir uma amplificação igual de todos eles. O teste possui 
um controle interno e foi padronizado com um painel internacional de 
HBV. Sua eficácia foi testada comparando-se os resultados com outros 
dois métodos: Versant HBV DNA Assay 3.0 (bDNA, Siemens, NY, USA) 
e outro PCR em tempo real realizado em um laboratório de referência. 
As reprodutibilidades intra e inter-ensaio foram determinadas e a média 
dos valores de CV obtidos foram de 0,12 e 0,09, respectivamente. O 
teste foi validado com uma ampla faixa dinâmica e amplificou com 
eficiência os diferentes genótipos de HBV, fornecendo uma boa opção 
para a quantificação de rotina do DNA do HBV, com um protocolo 
barato e confiável. 
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